Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows ...

What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the ...

Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million.

Myriad Genetics lowered its full-year revenue guidance, as second quarter sales fell due to volume challenges in prenatal health and increased payer friction. The genetic testing and precision ...

View SOPHiA GENETICS SA SOPH stock quote prices, financial information, real-time forecasts, and company news from CNN.

Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging ...

Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic ...

SOPHiA GENETICS President and CEO Ross Muken discusses the use of AI and technology in diagnosing and treating patients, ...

Researchers have identified the first evidence of genetic risk factors associated with borderline personality disorder (BPD).